Patent intelligence · US
US 8153609
Purine nucleotide derivatives
Purine nucleotide derivatives
Patent details — US 8153609
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 10, 2012
- Expiration
- Apr 5, 2032
- Applicant
- Lauras AS
- Claims
- 22
- CPC classes
- A61P, A61P31/18, A61P37/00, A61P37/04
Quick answer
US 8153609 (Purine nucleotide derivatives) is held by Lauras AS. Status: granted. Granted Apr 10, 2012. Expires Apr 5, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lauras AS
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61P, A61P31/18, A61P37/00, A61P37/04, A61P43/00
More from Lauras AS
Related pharmaceutical patents in our USPTO index.
-
US 11786503
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 11166936
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10874633
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10806716
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10688172
HPV particles and uses thereof
granted -
US 10596275
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10300150
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10179168
HPV particles and uses thereof
granted
Frequently asked questions
What is US patent 8153609?
US 8153609 (Purine nucleotide derivatives) is held by Lauras AS. Status: granted. Granted Apr 10, 2012. Expires Apr 5, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8153609?
Lauras AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 8153609 expire?
Our index shows an expiration date of Apr 5, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.